References
- 1. Knuuti J., Wijns W., Saraste A. et al. (2019) ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology. Eur. Heart J., 41(3): 407–477. doi.org/10.1093/eurheartj/ehz425.
- 2. Cattaneo M., Halasz G., Cattaneo M.M. et al. (2022) The Central Nervous System and Psychosocial Factors in Primary Microvascular Angina. Front. Cardiovasc. Med., 9: 896042. doi.org/10.3389/fcvm.2022.896042.
- 3. Ismaiel A., Spinu M., Leucuta D.C. et al. (2022) Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk. J. Clin. Med., 11(9): 2488. doi.org/10.3390/jcm11092488.
- 4. Kofler T., Hess S., Moccetti F. et al. (2020) Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction-A Systematic Review and Meta-analysis of Randomized Trials. Canad. J. Cardiol., 3(1): 101–108. doi.org/10.1016/j.cjco.2020.09.005.
- 5. Reed M., Kerndt C.C., Gopal S., Nicolas D. (2023) Ranolazine. StatPearls. Treasure Island (FL): StatPearls Publ.
- 6. Sharp R.P., Patatanian E., Sirajuddin R. (2021) Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. Am. J. Cardiovasc. Drugs, 21(5): 513–521. doi.org/10.1007/s40256-020-00462-6.
- 7. Maulana S., Nuraeni A., Nugraha B.A. (2022) The Potential of Prognostic Biomarkers of Uric Acid Levels in Coronary Heart Disease Among Aged Population: A Scoping Systematic Review of the Latest Cohort Evidence. J. Multidiscip Healthc, 15: 161–173. doi.org/10.2147/JMDH.S340596.
- 8. Kaplan A., Amin G., Abidi E. et al. (2022) Role of ranolazine in heart failure: From cellular to clinic perspective. Eur. J. Pharmacol., 919: 174787. doi.org/10.1016/j.ejphar.2022.174787.
- 9. Lovelock J.D., Monasky M.M., Jeong E.M. et al. (2012) Ranolazine improves cardiac dysfunction through modulation of myofilament calcium sensitivity. Circ. Res., 110: 841–850. doi: 10.1161/CIRCRESAHA.111.258251.
- 10. Cattaneo M., Porretta A.P., Gallino A. (2015) Ranolazine: Drug overview and possible role in primary microvascular angina management. Int. J. Cardiol., 181: 376–381.
- 11. Putri D.K.S.C., Andrianto A., Al-Farabi M.J. et al. (2023) Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. Eur. Cardiol., 18: e02. doi: 10.15420/ecr.2022.10.
- 12. Ghosh G.C., Ghosh R.K., Bandyopadhyay D. et al. (2018) Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective. Heart Views, 19(3): 88–98. doi.org/10.4103/heartviews.heartviews_18_18.
- 13. Manolis A., Kallistratos M., Poulimenos L. et al. (2022) Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis. Hellenic J. Cardiol., S1109-9666(22)00176-2. doi: 10.1016/j.hjc.2022.12.002.
- 14. De Vecchis R., Ariano C., Giasi A., Cioppa C. (2018) Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardioangiol., 66(3): 349–359. doi: 10.23736/S0026-4725.17.04349-3.
- 15. Rosano G.M.C., Vitale C. (2018) Metabolic Modulation of Cardiac Metabolism in Heart Failure. Card. Fail. Rev., 4(2): 99–103. doi.org/10.15420/cfr.2018.18.2.
- 16. Volynskyi D., Vakaliuk I. (2019) Use Of Meldonium In The Treatment Of Patients With Coronary Artery Disease And Concomitant Arterial Hypertension. Eureka: Health Sciences, 6(6): 9–14. doi.org/10.21303/2504-5679.2019.001018.
- 17. Salazar C.A., Flores J.E.B., Espinoza L.E.V. et al. (2017) Ranolazine for stable angina pectoris. Cochrane Database Syst. Rev., 2(2): CD011747. doi: 10.1002/14651858.
- 18. Zweiker R., Aichinger J., Metzler B. et al. (2019) Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria — the ARETHA AT study. Wien Klin. Wochenschr., 131(7–8): 165–173. doi: 10.1007/s00508-019-1481-x.
- 19. Andrievskaya S., Krotenko V., Kolesnik V. (2019) New components of contemporary arrhythmology — the basics of pathogenesis and their clinical justification. Medicine of Ukraine, 16–23. doi: 10.37987/1997-9894.2019.8(234).187158.
- 20. Leelapatana P., Thongprayoon C., Prasitlumkum N. et al. (2021) Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials. Diseases, 9(2): 31. doi: 10.3390/diseases9020031.